In This Article:
Entrada Therapeutics (NASDAQ:TRDA) Third Quarter 2024 Results
Key Financial Results
-
Revenue: US$19.6m (down 55% from 3Q 2023).
-
Net loss: US$14.0m (down by 140% from US$35.5m profit in 3Q 2023).
-
US$0.34 loss per share (down from US$1.07 profit in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Entrada Therapeutics Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 65%. Earnings per share (EPS) also surpassed analyst estimates by 56%.
Looking ahead, revenue is expected to decline by 81% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 21%.
Performance of the American Biotechs industry.
The company's shares are up 7.8% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Entrada Therapeutics (1 is a bit concerning) you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.